RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and
Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA (1)and Revises Upwards 2026 Financial Guidance Ranges
Total Company Revenue increased 22.1% to $638.3 million in the third quarter · of 2026 from $522.9 million in the third quarter of 2025; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 32.6% to $32.9 million in the third quarter of 2026 from $24.8 million in the third quarter of 2025 Total Company Adjusted EBITDA(1) was $105.0 million in the third quarter of 2026 as compared with $84.9 million in the third quarter · of 2025, an increase of 23.8%; Digital Health reportable segment Adjusted EBITDA(1) decreased 11.8% to $3.0 million in the third quarter of 2026 from $3.5 million in the third quarter of 2025 Total Company Adjusted EBITDA(1) margin increased to 16.5% · in the third quarter of 2026 as compared with 16.2% in the third quarter of 2025 Adjusting for unusual or one-time items in the quarter, Adjusted Diluted · Earnings Per Share(3) was $0.30 for the third quarter of 2026; This compares with Adjusted Diluted Earnings Per Share(3) of $0.24 for the third quarter of 2025 In the third quarter of 2026, aggregate advanced imaging (MRI, CT and · PET/CT) procedural volumes increased 19.9% and same-center advanced imaging procedural volumes increased 8.9% as compared with the third quarter of 2025 · As of September 30, 2026, we had a cash balance of $750.6 million and Net Debt to Adjusted EBITDA(1) ratio of 1.66x · RadNet revises full-year 2026 guidance levels to increase Imaging Center Revenue, Adjusted EBITDA(1)and Free Cash Flow(2) ranges
LOS ANGELES, California, November 8, 2026 – RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2026.
Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “We delivered record quarterly Revenue and Adjusted EBITDA in the third quarter. Total Company Revenue grew 22.1% and Adjusted EBITDA grew 23.8% compared with last year’s third quarter, and Adjusted EBITDA margin expanded 23 basis points. These results were driven by continued initiatives to create and fill capacity at existing imaging centers, new center openings, the continued shift in the business mix towards advanced imaging, tuck-in acquisitions, improved reimbursement from commercial payors, the expansion of our health system joint ventures and 32.6% Revenue growth in the Digital Health segment.”
Dr. Berger continued, “Advanced imaging growth continues to be strong, both in aggregate and on a same-center basis. Compared with last year’s third quarter, aggregate advanced imaging procedural volumes increased 19.9% and same-center advanced imaging procedural volumes increased 8.9%. As a result, RadNet’s advanced imaging business mix increased 232 basis points, from 28.2% of all procedures in the third quarter of 2025 to 30.6% in the third quarter of 2026.”
“With strong performance across nearly every part of the core imaging center business, we are again raising certain guidance ranges in anticipation that full-year results will exceed both our original expectations and the revised ranges issued in conjunction with first and second quarter 2026 results. We are raising 2026 Imaging Center guidance ranges for Revenue, Adjusted EBITDA and Free Cash Flow,” added Dr. Berger.
Dr. Berger continued, “We are particularly excited about the opportunities for growth and expansion that will be made possible as a result of the recently announced pending acquisition of ONRAD. The inbound interest from current joint venture partners and potential new partners and customers has exceeded our expectations. The strategic fit that ONRAD’s capabilities have with both RadNet’s core imaging center business and Digital Health solutions is already being recognized in the imaging marketplace, and we look forward to the opportunities that could result once the acquisition is closed.”
“RadNet’s balance sheet remains healthy and continues to provide the operating flexibility necessary to achieve further growth. We ended the third quarter with $750.6 million in cash and a Net Debt to Adjusted EBITDA leverage ratio of 1.66x. This liquidity enables us to keep investing in organic growth and to pursue attractive strategic acquisitions in the coming quarters,” concluded Dr. Berger.
For the third quarter of 2026, RadNet reported Total Company Revenue of $638.3 million and Adjusted EBITDA of $105.0 million. Revenue increased $115.4 million (or 22.1%) and Adjusted EBITDA increased $20.2 million (or 23.8%) as compared with the third quarter of 2025.
For the third quarter of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $32.9 million and Adjusted EBITDA of $3.0 million. Revenue increased $8.1 million (or 32.6%) and Adjusted EBITDA decreased $0.4 million (or -11.8%) as compared with the third quarter of 2025.
Unadjusted for unusual or one-time items impacting the third quarter, Total Company Net Income for the third quarter of 2026 was $4.2 million as compared with a Total Company Net Income of $5.4 million for the third quarter of 2025. Fully diluted Net Income Per Share for the third quarter of 2026 was $0.05, compared with a fully diluted Net Income Per Share of $0.07 in the third quarter of 2025, based upon a weighted average number of diluted shares outstanding of 79.2 million shares in the third quarter of 2026 and 77.4 million shares in the third quarter of 2025.
There were a number of unusual, one-time and noteworthy items impacting the third quarter including: $1.2 million in severance expense related to cost-savings initiatives; $7.5 million gain on the contribution of imaging centers into joint ventures; $0.6 million expense related to leases for de novo facilities under construction that have yet to open their operations; $5.4 million loss on the disposal of equipment; $7.3 million intangibles amortization expense related to the Digital Health operating segment; $5.6 million of non-capitalized research and development expenses related to the DeepHealth Cloud OS and AI solutions; $2.8 million in legal settlements; $2.7 million of acquisition transaction costs; $8.3 million in non-cash change in contingent consideration; and $2.1 million of lease abandonment charges. Adjusting for the above items, Total Company Adjusted Earnings was $23.8 million and diluted Adjusted Earnings Per Share was $0.30 during the third quarter of 2026. This compares with Total Company Adjusted Earnings of $18.8 million and diluted Adjusted Earnings Per Share of $0.24 during the third quarter of 2025.
For the third quarter of 2026, as compared with the prior year’s third quarter, MRI volume increased 18.3%, CT volume increased 22.0% and PET/CT volume increased 30.4%. Overall volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 10.8% over the prior year’s third quarter. On a same-center basis, including only those centers which were part of RadNet for both the third quarters of 2026 and 2025, MRI volume increased 8.2%, CT volume increased 10.2% and PET/CT volume increased 8.2%. Overall same-center volume, taking into account routine imaging exams, inclusive of x-ray, ultrasound, mammography and other exams, increased 3.2% over the prior year’s same quarter
For the first nine months of 2026, RadNet reported Total Company Revenue of $1,836.6 million and Adjusted EBITDA of $268.0 million. Revenue increased $344.1 million (or 23.1%) and Adjusted EBITDA increased $55.4 million (or 26.1%) as compared with the first nine months of 2025.
For the first nine months of 2026, RadNet reported Digital Health Revenue (inclusive of intersegment revenue) of $94.5 million and Adjusted EBITDA of $6.8 million. Revenue increased $29.7 million (or 45.8%) and Adjusted EBITDA decreased $3.7 million (or -35.4%) as compared with the first nine months of 2025.
Unadjusted for one-time or unusual items, Total Company Net Loss for the first nine months of 2026 was $21.8 million as compared with a Total Company Net Loss of $18.1 million for the first nine months of 2025. Fully diluted Net Loss Per Share for the nine month period of 2026 was $(0.28), compared with a fully diluted Net Loss Per Share of $(0.24) in the nine month period of 2025, based upon a weighted average number of diluted shares outstanding of 77.6 million shares for the nine month period in 2026 and 74.7 million shares for the nine month period in 2025.
Revised Revised Revised Original Guidance Guidance Guidance Guidance Range Range After Range After Range After Q1 Q2 Results Q3 Results Results Total Net $2,325 - $2,355 - $2,370 - $2,385 - Revenue $2,375 $2,405 $2,420 $2,435 million million million million Adjusted $335 - $348 $340 - $353 $345 - $358 $350 - $363 EBITDA(1) million million million million Capital $165 - $175 $165 - $175 $165 - $175 $170 - $180 Expenditur… million million million million Cash $45 - $50 $45 - $50 $48 - $53 $48 - $53 Interest million million million million Expense(b) Free Cash $105 - $115 $112 - $122 $115 - $125 $120 - $130 Flow (2) million million million million
Net of proceeds from the sale of equipment and the New Jersey Imaging (a) Network L.L.C. joint venture capital expenditures.
Net of payments received from counterparties on interest rate swaps and (b) interest income from our cash balance recorded in Other Income.
Revised Revised Revised Original Guidance Guidance Guidance Guidance Range After Range After Range After Range Q1 Q2 Q3 Results Results Results Total Net Revenue $135 (inclusive - $145 $135 - $145 $135 - $145 $135 - $145 of million million million million intersegme… revenue) Adjusted EBITDA(1) Before Non-Capita… $10 - $12 $10 - $12 $10 - $12 $11 - $13 R&D - million million million million DeepHealth Cloud OS & Generative AI Non-Capita… R&D - DeepHealth $17 - $19 $17 - $19 $17 - $19 $17 - $19 Cloud million million million million OS & Generative AI Capital $9 - $12 $9 - $12 $9 - $12 $10 - $13 Expenditur… million million million million Free Cash Flow(2) Before Non-Capita… $(1) - $3 $(1) - $3 $(1) - $3 $(1) - $3 R&D - million million million million DeepHealth Cloud OS & Generative AI Free Cash Flow(2) After Non-Capita… $(17) - $(17) - $(17) - $(19) $(17) - R&D - $(19) $(19) million $(19) DeepHealth million million million Cloud OS & Generative AI
Dr. Berger explained, “The Imaging Center segment has outperformed projections in each of the first three quarters of this year. As a result, we are raising its guidance ranges for Revenue, Adjusted EBITDA and Free Cash Flow. In the Digital Health segment, we are raising the Adjusted EBITDA guidance range as a result of effective expense management and faster- than-projected integration of acquired operations.”
Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will host a conference call to discuss its third quarter 2026 results on Monday, November 9th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
It is recommended that participants dial in approximately 5 minutes prior to the start of the 10:30 a.m. call. There will also be simultaneous and archived webcasts available athttps://viavid.webcasts.com/starthere.jsp?ei=1780998&tp_key=f33fc0e8e8 or http://www.radnet.com under the “Investors” menu section and “News Releases” sub-menu of the website. An archived replay of the call will also be available and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for international callers, and using the passcode 10213035.
RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 12,000 team members. Learn more at www.radnet.com.
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are expressions of our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, and anticipated future conditions, events and trends. Forward-looking statements can generally be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. Forward- looking statements in this press release include, among others, statements about our anticipated business results, balance sheet and liquidity and our future liquidity, burn rate and our continuing ability to service or refinance our current indebtedness.
Forward-looking statements are neither historical facts nor assurances of future performance. Because forward-looking statements relate to the future, they are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward- looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:
· the availability and terms of capital to fund our business; our ability to service our indebtedness, make · principal and interest payments as those payments become due and remain in compliance with applicable debt covenants, in addition to our ability to refinance such indebtedness on acceptable terms; · changes in general economic conditions nationally and regionally in the markets in which we operate; the availability and terms of capital to fund · the expansion of our business and improvements to our existing facilities; our ability to maintain our current credit rating · and the impact on our funding costs and competitive position if we do not do so; our ability to acquire, develop, implement and monetize technology, · digital health initiatives, artificial intelligence algorithms and applications; · volatility in interest and exchange rates, or credit markets; · the adequacy of our cash flow and earnings to fund our current and future operations; · changes in service mix, revenue mix and procedure volumes; · delays in receiving payments for services provided; · increased bankruptcies among our partner physicians or joint venture partners; the impact of the political environment and related · developments on the current healthcare marketplace and on our business, including with respect to the future of the Affordable Care Act; the extent to which the ongoing implementation of healthcare reform, or changes in or new legislation, regulations or · guidance, enforcement thereof by federal and state regulators or related litigation result in a reduction in coverage or reimbursement rates for our services, or other material impacts to our business; closures or slowdowns and changes in labor costs · and labor difficulties, including stoppages affecting either our operations or our suppliers' abilities to deliver supplies needed in our facilities; · the occurrence of hostilities, political instability or catastrophic events; · the emergence or reemergence of and effects related to future pandemics, epidemics and infectious diseases; and noncompliance by us with any privacy or security · laws or any cybersecurity incident or other security breach by us or a third party involving the misappropriation, loss or other unauthorized use or disclosure of confidential information.
Any forward-looking statement contained in this current report is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that we may make from time to time, whether as a result of changed circumstances, new information, future developments or otherwise, except as required by applicable law.
This release contains certain financial information not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP metrics to measure its financial results. The Company believes that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in measuring its cash-based performance. The Company believes this information is useful to investors and other interested parties because it removes unusual and nonrecurring charges that occur in the affected period and provides a basis for measuring the Company's financial condition against other quarters. Such information should not be considered as a substitute for any measures calculated in accordance with GAAP, and may not be comparable to other similarly titled measures of other companies. Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Reconciliation of this information to the most comparable GAAP measures is included in this release in the tables which follow.
September 30, December 31, 2026 2025 ────────────────────────────────────────────────────────────────────────────── -unaudited ASSETS CURRENT ASSETS Cash and Cash $ 750,607 $ 767,215 equivalents Accounts 248,893 200,317 receivable Due from 5,600 12,592 affiliates Prepaid expenses and other 63,341 52,003 current assets Total current 1,068,441 1,032,127 assets PROPERTY, EQUIPMENT AND RIGHT-OF-USE ASSETS Property and equipment, 904,274 807,702 net Operating lease 755,606 690,250 right-of-use assets Total property, equipment 1,659,880 1,497,952 and right-of-use assets OTHER ASSETS Goodwill 1,136,986 907,663 Other intangible 235,063 148,508 assets Deferred financing 1,248 1,684 costs Investment in joint 131,507 130,340 ventures Deposits and 47,273 40,289 other Total Assets $ 4,280,398 $ 3,758,563 LIABILITIES AND EQUITY CURRENT LIABILITIES Accounts payable, accrued $ 500,750 $ 422,029 expenses and other Due to 96,065 70,104 affiliates Deferred 16,116 7,272 revenue Current operating 70,598 61,934 lease liability Current portion of 31,796 25,424 notes payable Current portion of 1,317 – finance lease Total current 716,642 586,763 liabilities LONG-TERM LIABILITIES Long-term finance 3,951 – lease liability Long-term operating 772,771 707,001 lease liability Notes payable, net 1,293,505 1,064,495 of current portion Deferred tax liability, 46,457 21,903 net Other non-current 10,193 22,515 liabilities Total 2,843,519 2,402,677 liabilities EQUITY RadNet, Inc. stockholder… equity: Common stock - $0.0001 par value, 200,000,000 shares authorized; 78,768,800 and 77,399,615 8 8 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively Additional 1,246,319 1,180,434 paid-in-cap… Accumulated other comprehensi… (7,811 ) 4,885 (loss) income Accumulated (117,220 ) (95,437 ) deficit Total RadNet, Inc.'s 1,121,296 1,089,890 Stockholder… equity:
CASH FLOWS FROM Nine Months Ended OPERATING September 30, ACTIVITIES 2026 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 14,673 $ 7,186 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 137,506 111,275 amortization Noncash operating 49,425 44,605 lease expense Equity in earnings of joint ventures, (4,244 ) (4,590 ) net of dividends Amortization of deferred financing 2,355 2,242 costs and loan discount Loss on sale and disposal of 9,067 3,168 equipment Loss on extinguishment of 407 – debt Gain on contribution of (7,528 ) – imaging centers into joint venture Lease abandonment 3,358 8,330 charges Amortization of – 2,273 cash flow hedge Non-cash change in fair value of – 6,433 interest rate swap Stock-based 51,933 46,276 compensation Change in fair value of 7,864 – contingent consideration Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions:
Accounts (30,461 ) (20,476 ) receivable Other current (4,292 ) 2,093 assets Other assets (7,478 ) (2,764 ) Deferred taxes 4,334 2 Operating leases (45,252 ) (48,760 ) Deferred revenue 581 3,934 Accounts payable, accrued expenses 81,393 53,429 and other Net cash provided by operating 263,641 214,656 activities CASH FLOWS FROM INVESTING ACTIVITIES Purchase of imaging facilities and other (315,708 ) (66,464 ) acquisitions, net of cash acquired Purchase of property and (181,721 ) (162,221 ) equipment and other Proceeds from sale 1,270 75 of equipment Equity contributions in existing and – (4,147 ) purchase of interest in joint ventures Collection of 8,541 2,832 notes receivable Net cash used in investing (487,618 ) (229,925 ) activities CASH FLOWS FROM FINANCING ACTIVITIES Principal payments on notes and (13,993 ) (5,229 ) leases payable Payments on Term (17,028 ) (15,504 ) Loan Debt Proceeds from issuance of new 248,937 99,001 debt, net of issuing costs Purchase of noncontrolling – 2,389 interests by third party Payments on contingent (2,198 ) – consideration and holdbacks Distributions paid to noncontrolling (8,362 ) (3,313 ) interests Proceeds from issuance of common stock 2,517 2,258 upon exercise of options Net cash provided by financing 209,873 79,602 activities EFFECT OF EXCHANGE RATE CHANGES ON (2,504 ) 363 CASH NET (DECREASE) INCREASE IN CASH (16,608 ) 64,696 AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, 767,215 740,020 beginning of period CASH AND CASH EQUIVALENTS, end 750,607 804,716 of period SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Cash paid during the period for $ 53,635 $ 53,679 interest Cash paid during the period for $ 3,908 $ 3,480 income taxes
RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON SHAREHOLDERS TO ADJUSTED EBITDA
Third Quarter 2026 Commercial Insurance 56.4% Medicare 24.8% Capitation 4.9% Medicaid 2.3% Workers Compensation/Personal Injury 2.1% Other* 9.5% Total 100.0%
* Includes management fee, teleradiology and Digital Health financial reporting unit revenue. RADNET PAYMENTS BY MODALITY
Three Months Ended 2026 September 30, 2025(iv) September 30, ────────────────────────────────────────────────────────────────────────────── NET INCOME (LOSS) ATTRIBUTABLE TO $ 4,153 $ 5,417 RADNET, INC.COMMON STOCKHOLDERS Non-cash impact of – 2,587 cash flow hedges (i) Severance 1,194 1,441 costs Loss (gain) on contribution of imaging (7,528 ) – centers into joint ventures Non-operatio… rent expenses 604 621 (iii) Loss (gain) on sale and disposal of 5,359 1,042 equipment and other Intangibles Amortization Expense - Digital 7,260 3,353 Health Operating Segment Non-capitali… R&D - DeepHealth 5,565 5,486 cloud OS & generative AI Legal 2,815 – Settlement Acquisition transaction 2,708 2,136 costs Non-cash change to 8,257 – contingent consideration Lease abandonment 2,052 2,819 charges Total adjustments - 28,286 19.485 loss (gain) Subtract tax impact of (8,596 ) (6,138 Adjustments (ii) Tax effected impact of 19,690 13,347 adjustments TOTAL ADJUSTMENT TO NET INCOME ATTRIBUTABLE 19,690 13,347 TO RADNET, INC. COMMON SHAREHOLDERS ADJUSTED NET INCOME (LOSS) ATTRIBUTABLE 23,843 18,764 TO RADNET, INC. COMMON STOCKHOLDERS WEIGHTED AVERAGE SHARES OUTSTANDING Diluted 79,174,226 77,388,477 ADJUSTED DILUTED NET INCOME PER SHARE $ 0.30 $ 0.24 ATTRIBUTABLE TO RADNET, INC. COMMON STOCKHOLDERS
Impact is the sum of (a) the loss in fair value of the hedges during the quarter of $2,371 in 2025 and (b) the amortization of the (i) accumulation of the changes in fair value out of Other Comprehensive Income that existed prior to the hedges becoming ineffective of $216 in 2025. (ii) Tax effected using 31.5% blended federal and state effective tax rate for 2025 and 30.4% for 2026. Represents rent expense associated with de novo sites under (iii) construction prior to them becoming operational. Adjusted from what was reported during last year's third quarter for additional addbacks of (a) $1,042,000 related to Loss (gain) on (iv) sale and disposal of equipment and other and (b) Intangible amortization expense of the Digital Health operating segment of $3,353,000.
The Company defines Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, each from continuing operations and adjusted for losses or gains on the sale of equipment, other income or loss, debt extinguishments and non-cash equity compensation. Adjusted EBITDA includes equity earnings in unconsolidated operations and subtracts allocations of earnings to non- controlling interests in subsidiaries, and is adjusted for non-cash or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance, and is a measure of leverage capacity and ability to service debt. Adjusted EBITDA should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
As noted above, the Company defines Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether completed with cash or financed) and Cash Interest Expense. Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow because the Company believes it provides useful information for investors and management because it measures our capacity to generate cash from our operating activities. Free Cash Flow does not represent total cash flow since it does not include the cash flows generated by or used in financing activities. In addition, our definition of Free Cash Flow may differ from definitions used by other companies.
Free Cash Flow should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted EBITDA is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
The Company defines Adjusted Earnings (Loss) Per Share as net income or loss attributable to RadNet, Inc. common stockholders and excludes losses or gains on the disposal of equipment, loss on debt extinguishments, bargain purchase gains, severance costs, loss on impairment, loss or gain on swap valuation, gain on extinguishment of debt, unusual or non-recurring entries that impact the Company’s tax provision and any other non-recurring or unusual transactions recorded during the period.
Adjusted Earnings (Loss) Per Share is reconciled to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per Share is a non-GAAP financial measure used as analytical indicator by RadNet management and the healthcare industry to assess business performance. Adjusted Earnings Per Share should not be considered a measure of financial performance under GAAP, and the items excluded from Adjusted Earnings Per Share should not be considered in isolation or as alternatives to net income, cash flows generated by operating, investing or financing activities or other financial statement data presented in the consolidated financial statements as an indicator of financial performance or liquidity. As Adjusted Earnings Per Share is not a measurement determined in accordance with GAAP and is therefore susceptible to varying methods of calculation, this metric, as presented, may not be comparable to other similarly titled measures of other companies.
Full text with the tables
Exhibit 99.1
FOR IMMEDIATE RELEASE
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and
Adjusted EBITDA (1)and Revises Upwards 2026 Financial Guidance Ranges
Total Company Revenue increased 22.1% to $638.3 million in the third
quarter
· of 2026 from $522.9 million in the third quarter of 2025; Revenue from
the Digital Health reportable segment (inclusive of intersegment
revenue) increased 32.6% to $32.9 million in the third quarter of 2026
from $24.8 million in the third quarter of 2025
Total Company Adjusted EBITDA(1) was $105.0 million in the
third quarter of 2026 as compared with $84.9 million in the third quarter
· of 2025, an increase of 23.8%; Digital Health reportable segment
Adjusted EBITDA(1) decreased 11.8% to $3.0 million in the third quarter
of 2026 from $3.5 million in the third quarter of 2025
Total Company Adjusted EBITDA(1) margin increased to 16.5%
· in the third quarter of 2026 as compared with 16.2% in the third quarter
of 2025
Adjusting for unusual or one-time items in the quarter, Adjusted Diluted
· Earnings Per Share(3) was $0.30 for the third quarter of 2026; This
compares with Adjusted Diluted Earnings Per Share(3)
of $0.24 for the third quarter of 2025
In the third quarter of 2026, aggregate advanced imaging (MRI, CT and
· PET/CT) procedural volumes increased 19.9% and same-center advanced
imaging procedural volumes increased 8.9% as compared with the third
quarter of 2025
· As of September 30, 2026, we had a cash balance of $750.6 million and
Net Debt to Adjusted EBITDA(1) ratio of 1.66x
· RadNet revises full-year 2026 guidance levels to increase Imaging Center
Revenue, Adjusted EBITDA(1)and Free Cash Flow(2) ranges
LOS ANGELES, California, November 8, 2026 – RadNet, Inc. (NASDAQ: RDNT), a
national leader in providing high-quality, cost-effective outpatient diagnostic
imaging services and
a premier global developer of digital health solutions, today reported financial
results for its third quarter of 2026.
Dr. Howard Berger, President and Chief Executive
Officer of RadNet, commented, “We delivered record quarterly Revenue and
Adjusted EBITDA in the third quarter. Total
Company Revenue grew 22.1% and Adjusted EBITDA grew 23.8% compared with last
year’s third quarter, and Adjusted EBITDA
margin expanded 23 basis points. These results were driven by continued
initiatives to create and fill capacity at existing imaging centers,
new center openings, the continued shift in the business mix towards advanced
imaging, tuck-in acquisitions, improved reimbursement from
commercial payors, the expansion of our health system joint ventures and 32.6%
Revenue growth in the Digital Health segment.”
1
Dr. Berger continued, “Advanced imaging
growth continues to be strong, both in aggregate and on a same-center basis.
Compared with last year’s third quarter, aggregate
advanced imaging procedural volumes increased 19.9% and same-center advanced
imaging procedural volumes increased 8.9%. As a result, RadNet’s
advanced imaging business mix increased 232 basis points, from 28.2% of all
procedures in the third quarter of 2025 to 30.6% in the third
quarter of 2026.”
“With strong performance across nearly every
part of the core imaging center business, we are again raising certain guidance
ranges in anticipation that full-year results will exceed
both our original expectations and the revised ranges issued in conjunction with
first and second quarter 2026 results. We are raising
2026 Imaging Center guidance ranges for Revenue, Adjusted EBITDA and Free Cash
Flow,” added Dr. Berger.
Dr. Berger continued, “We are particularly
excited about the opportunities for growth and expansion that will be made
possible as a result of the recently announced pending acquisition
of ONRAD. The inbound interest from current joint venture partners and potential
new partners and customers has exceeded our expectations.
The strategic fit that ONRAD’s capabilities have with both RadNet’s core imaging
center business and Digital Health solutions
is already being recognized in the imaging marketplace, and we look forward to
the opportunities that could result once the acquisition
is closed.”
“RadNet’s balance sheet remains healthy
and continues to provide the operating flexibility necessary to achieve further
growth. We ended the third quarter with $750.6 million
in cash and a Net Debt to Adjusted EBITDA leverage ratio of 1.66x. This
liquidity enables us to keep investing in organic
growth and to pursue attractive strategic acquisitions in the coming quarters,”
concluded Dr. Berger.
2
Third Quarter Financial Results
For the third quarter of 2026, RadNet reported
Total Company Revenue of $638.3 million and Adjusted EBITDA of $105.0 million.
Revenue increased $115.4 million (or 22.1%)
and Adjusted EBITDA increased $20.2 million (or 23.8%) as compared with the
third quarter of 2025.
For the third quarter of 2026, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $32.9 million and
Adjusted EBITDA of $3.0 million. Revenue
increased $8.1 million (or 32.6%) and Adjusted EBITDA decreased $0.4 million (or
-11.8%) as compared with the third quarter
of 2025.
Unadjusted for unusual or one-time items impacting
the third quarter, Total Company Net Income for the third quarter of 2026 was
$4.2 million as compared with a Total Company Net Income
of $5.4 million for the third quarter of 2025. Fully diluted Net Income Per
Share for the third quarter of 2026 was $0.05, compared with
a fully diluted Net Income Per Share of $0.07 in the third quarter of 2025,
based upon a weighted average number of diluted shares outstanding
of 79.2 million shares in the third quarter of 2026 and 77.4 million shares in
the third quarter of 2025.
There were a number of unusual, one-time and noteworthy
items impacting the third quarter including: $1.2 million in severance expense
related to cost-savings initiatives; $7.5 million gain
on the contribution of imaging centers into joint ventures; $0.6 million expense
related to leases for de novo facilities under construction
that have yet to open their operations; $5.4 million loss on the disposal of
equipment; $7.3 million intangibles amortization expense
related to the Digital Health operating segment; $5.6 million of non-capitalized
research and development expenses related to the DeepHealth
Cloud OS and AI solutions; $2.8 million in legal settlements; $2.7 million of
acquisition transaction costs; $8.3 million in non-cash
change in contingent consideration; and $2.1 million of lease abandonment
charges. Adjusting for the above items, Total Company Adjusted
Earnings was $23.8 million and diluted Adjusted Earnings Per Share was $0.30
during the third quarter of 2026.
This compares with Total Company Adjusted Earnings of $18.8 million and diluted
Adjusted Earnings Per Share
of $0.24 during the third quarter of 2025.
For the third quarter of 2026, as compared with
the prior year’s third quarter, MRI volume increased 18.3%, CT volume increased
22.0% and PET/CT volume increased 30.4%. Overall
volume, taking into account routine imaging exams, inclusive of x-ray,
ultrasound, mammography and other exams, increased 10.8% over the
prior year’s third quarter. On a same-center basis, including only those centers
which were part of RadNet for both the third quarters
of 2026 and 2025, MRI volume increased 8.2%, CT volume increased 10.2% and
PET/CT volume increased 8.2%. Overall same-center volume, taking
into account routine imaging exams, inclusive of x-ray, ultrasound, mammography
and other exams, increased 3.2% over the prior year’s
same quarter
Nine Month Financial Results
For the first nine months of 2026, RadNet reported
Total Company Revenue of $1,836.6 million and Adjusted EBITDA of $268.0 million.
Revenue increased $344.1 million (or 23.1%)
and Adjusted EBITDA increased $55.4 million (or 26.1%) as compared with the
first nine months of 2025.
For the first nine months of 2026, RadNet reported
Digital Health Revenue (inclusive of intersegment revenue) of $94.5 million and
Adjusted EBITDA of $6.8 million. Revenue
increased $29.7 million (or 45.8%) and Adjusted EBITDA decreased $3.7 million
(or -35.4%) as compared with the first nine
months of 2025.
Unadjusted for one-time or unusual items, Total
Company Net Loss for the first nine months of 2026 was $21.8 million as compared
with a Total Company Net Loss of $18.1 million for the
first nine months of 2025. Fully diluted Net Loss Per Share for the nine month
period of 2026 was $(0.28), compared with a fully diluted
Net Loss Per Share of $(0.24) in the nine month period of 2025, based upon a
weighted average number of diluted shares outstanding of
77.6 million shares for the nine month period in 2026 and 74.7 million shares
for the nine month period in 2025.
3
2026 Guidance Update
RadNet amends its previously announced guidance
levels as follows:
Revised Revised Revised
Original Guidance Guidance Guidance
Guidance Range Range After Range After
Range After Q1 Q2 Results Q3 Results
Results
Total Net $2,325 - $2,355 - $2,370 - $2,385 -
Revenue $2,375 $2,405 $2,420 $2,435
million million million million
Adjusted $335 - $348 $340 - $353 $345 - $358 $350 - $363
EBITDA(1) million million million million
Capital $165 - $175 $165 - $175 $165 - $175 $170 - $180
Expenditur… million million million million
Cash $45 - $50 $45 - $50 $48 - $53 $48 - $53
Interest million million million million
Expense(b)
Free Cash $105 - $115 $112 - $122 $115 - $125 $120 - $130
Flow (2) million million million million
Net of proceeds from the sale of equipment and the New Jersey Imaging
(a) Network L.L.C. joint venture capital
expenditures.
Net of payments received from counterparties on interest rate swaps and
(b) interest income from our cash
balance recorded in Other Income.
Revised Revised Revised
Original Guidance Guidance Guidance
Guidance Range After Range After Range After
Range Q1 Q2 Q3
Results Results Results
Total Net
Revenue $135
(inclusive - $145 $135 - $145 $135 - $145 $135 - $145
of million million million million
intersegme…
revenue)
Adjusted
EBITDA(1)
Before
Non-Capita… $10 - $12 $10 - $12 $10 - $12 $11 - $13
R&D - million million million million
DeepHealth
Cloud OS &
Generative
AI
Non-Capita…
R&D -
DeepHealth $17 - $19 $17 - $19 $17 - $19 $17 - $19
Cloud million million million million
OS &
Generative
AI
Capital $9 - $12 $9 - $12 $9 - $12 $10 - $13
Expenditur… million million million million
Free Cash
Flow(2)
Before
Non-Capita… $(1) - $3 $(1) - $3 $(1) - $3 $(1) - $3
R&D - million million million million
DeepHealth
Cloud OS &
Generative
AI
Free Cash
Flow(2)
After
Non-Capita… $(17) - $(17) - $(17) - $(19) $(17) -
R&D - $(19) $(19) million $(19)
DeepHealth million million million
Cloud OS &
Generative
AI
Dr. Berger explained, “The Imaging Center
segment has outperformed projections in each of the first three quarters of this
year. As a result, we are raising its guidance ranges
for Revenue, Adjusted EBITDA and Free Cash Flow. In the Digital Health segment,
we are raising the Adjusted
EBITDA guidance range as a result of effective expense management and faster-
than-projected integration of acquired operations.”
4
Conference Call for Tomorrow
Dr. Howard Berger, President and Chief Executive
Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer,
will host a conference call to discuss its third quarter
2026 results on Monday, November 9th, 2026 at 7:30 a.m. Pacific Time (10:30 a.m.
Eastern Time).
Conference Call Details:
Date: Monday, November 9, 2026
Time: 10:30 a.m. Eastern Time
Dial In-Number: 844-744-1280
International Dial-In Number: 412-564-6465
It is recommended that participants dial in approximately 5 minutes prior to the
start of the 10:30 a.m. call. There will also be simultaneous and archived
webcasts available
athttps://viavid.webcasts.com/starthere.jsp?ei=1780998&tp_key=f33fc0e8e8
or http://www.radnet.com under the “Investors” menu section and “News Releases”
sub-menu of the website. An archived replay of the call will also be available
and can be accessed by dialing 844-512-2921 from the U.S., or 412-317-6671 for
international callers, and using the passcode 10213035.
About RadNet, Inc.
RadNet, Inc. is a leading national provider of
freestanding, fixed-site diagnostic imaging services in the United States based
on the number of locations and annual imaging revenue.
RadNet has a network of owned and/or operated outpatient imaging centers.
RadNet’s imaging center markets include Arizona, California,
Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and
Virginia. In addition, RadNet provides radiology information
technology and artificial intelligence solutions marketed under the DeepHealth
brand, teleradiology professional services and other related
products and services to customers in the diagnostic imaging industry globally.
Together with contracted radiologists, and inclusive of
full-time and per diem employees and technologists, RadNet has over 12,000 team
members. Learn more at www.radnet.com.
5
Forward Looking Statements
This press release contains “forward-looking
statements” within the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are expressions of our current beliefs, expectations and assumptions
regarding the future of our business, future plans and
strategies, projections, and anticipated future conditions, events and trends.
Forward-looking statements can generally be identified
by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,”
“project,” “estimate,” “expect,” “strategy,” “future,” “likely,”
“may,” “should,” “will” and similar references to future periods. Forward-
looking statements in this
press release include, among others, statements about our anticipated business
results, balance sheet and liquidity and our future liquidity,
burn rate and our continuing ability to service or refinance our current
indebtedness.
Forward-looking statements are neither historical
facts nor assurances of future performance. Because forward-looking statements
relate to the future, they are inherently subject to uncertainties,
risks and changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and
financial condition may differ materially from those indicated in the forward-
looking statements. Therefore, you should not place undue
reliance on any of these forward-looking statements. Important factors that
could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking statements
include, among others, the following:
· the availability and terms of capital to fund
our business;
our ability to service our indebtedness, make
· principal and interest payments as those payments become due and remain
in compliance with applicable debt covenants, in addition to our
ability to refinance such indebtedness on acceptable terms;
· changes in general economic conditions nationally
and regionally in the markets in which we operate;
the availability and terms of capital to fund
· the expansion of our business and improvements to our existing
facilities;
our ability to maintain our current credit rating
· and the impact on our funding costs and competitive position if we do not
do so;
our ability to acquire, develop, implement and monetize technology,
· digital health initiatives, artificial
intelligence algorithms and applications;
· volatility in interest and exchange rates, or
credit markets;
· the adequacy of our cash flow and earnings to
fund our current and future operations;
· changes in service mix, revenue mix and procedure
volumes;
· delays in receiving payments for services provided;
· increased bankruptcies among our partner physicians
or joint venture partners;
the impact of the political environment and related
· developments on the current healthcare marketplace and on our business,
including with respect to the future of the Affordable Care Act;
the extent to which the ongoing implementation
of healthcare reform, or changes in or new legislation, regulations or
· guidance, enforcement thereof by federal and state regulators or
related litigation result in a reduction in coverage or reimbursement
rates for our services, or other material impacts to our business;
closures or slowdowns and changes in labor costs
· and labor difficulties, including stoppages affecting either our
operations or our suppliers' abilities to deliver supplies needed in
our facilities;
· the occurrence of hostilities, political instability
or catastrophic events;
· the emergence or reemergence of and effects related
to future pandemics, epidemics and infectious diseases; and
noncompliance by us with any privacy or security
· laws or any cybersecurity incident or other security breach by us or a
third party involving the misappropriation, loss or other unauthorized
use or disclosure of confidential information.
Any forward-looking statement contained in this
current report is based on information currently available to us and speaks only
as of the date on which it is made. We undertake no obligation
to publicly update any forward-looking statement, whether written or oral, that
we may make from time to time, whether as a result of
changed circumstances, new information, future developments or otherwise, except
as required by applicable law.
6
Regulation G: GAAP and Non-GAAP Financial Information
This release contains certain financial information
not reported in accordance with GAAP. The Company uses both GAAP and non-GAAP
metrics to measure its financial results. The Company believes
that, in addition to GAAP metrics, these non-GAAP metrics assist the Company in
measuring its cash-based performance. The Company believes
this information is useful to investors and other interested parties because it
removes unusual and nonrecurring charges that occur in
the affected period and provides a basis for measuring the Company's financial
condition against other quarters. Such information should
not be considered as a substitute for any measures calculated in accordance with
GAAP, and may not be comparable to other similarly titled
measures of other companies. Non-GAAP financial measures should not be
considered in isolation from, or as a substitute for, financial
information prepared in accordance with GAAP. Reconciliation of this information
to the most comparable GAAP measures is included in this
release in the tables which follow.
CONTACTS:
RadNet, Inc.
Mark Stolper, 310-445-2800
Executive Vice President and Chief Financial Officer
7
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS EXCEPT SHARE AND PER SHARE DATA)
September 30, December 31,
2026 2025
──────────────────────────────────────────────────────────────────────────────
-unaudited
ASSETS
CURRENT
ASSETS
Cash and
Cash $ 750,607 $ 767,215
equivalents
Accounts 248,893 200,317
receivable
Due from 5,600 12,592
affiliates
Prepaid
expenses and
other 63,341 52,003
current
assets
Total
current 1,068,441 1,032,127
assets
PROPERTY,
EQUIPMENT
AND
RIGHT-OF-USE
ASSETS
Property and
equipment, 904,274 807,702
net
Operating
lease 755,606 690,250
right-of-use
assets
Total
property,
equipment 1,659,880 1,497,952
and
right-of-use
assets
OTHER ASSETS
Goodwill 1,136,986 907,663
Other
intangible 235,063 148,508
assets
Deferred
financing 1,248 1,684
costs
Investment
in joint 131,507 130,340
ventures
Deposits and 47,273 40,289
other
Total Assets $ 4,280,398 $ 3,758,563
LIABILITIES
AND EQUITY
CURRENT
LIABILITIES
Accounts
payable,
accrued $ 500,750 $ 422,029
expenses and
other
Due to 96,065 70,104
affiliates
Deferred 16,116 7,272
revenue
Current
operating 70,598 61,934
lease
liability
Current
portion of 31,796 25,424
notes
payable
Current
portion of 1,317 –
finance
lease
Total
current 716,642 586,763
liabilities
LONG-TERM
LIABILITIES
Long-term
finance 3,951 –
lease
liability
Long-term
operating 772,771 707,001
lease
liability
Notes
payable, net 1,293,505 1,064,495
of current
portion
Deferred tax
liability, 46,457 21,903
net
Other
non-current 10,193 22,515
liabilities
Total 2,843,519 2,402,677
liabilities
EQUITY
RadNet, Inc.
stockholder…
equity:
Common stock
- $0.0001
par value,
200,000,000
shares
authorized;
78,768,800
and
77,399,615 8 8
shares
issued
and
outstanding
at September
30, 2026
and December
31, 2025,
respectively
Additional 1,246,319 1,180,434
paid-in-cap…
Accumulated
other
comprehensi… (7,811 ) 4,885
(loss)
income
Accumulated (117,220 ) (95,437 )
deficit
Total
RadNet,
Inc.'s 1,121,296 1,089,890
Stockholder…
equity:
Noncontroll… 315,583 265,996
interests
Total Equity 1,436,879 1,355,886
Total
liabilities $ 4,280,398 $ 3,758,563
and equity
8
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(IN THOUSANDS EXCEPT FOR SHARE AND PER SHARE DATA)
(unaudited)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
30, 30,
REV… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Ser…
fee $ 607,… $ 491… $ 1,7… $ 1,39…
rev…
Rev…
und… 31,2… 31,… 91,… 93,6…
cap…
arr…
Tot…
ser… 638,… 522… 1,8… 1,49…
rev…
OPE…
EXP…
Cost
of
ope…
exc… 552,… 450… 1,6… 1,33…
dep…
and
amo…
Lea…
aba… 2,052 2,8… 3,3… 8,330
cha…
Dep…
and 47,0… 39,… 137… 111,…
amo…
Loss
(ga…
on
sale
and 5,359 1,0… 9,0… 3,168
dis…
of
equ…
and
oth…
Sev… 1,193 1,4… 3,3… 2,614
cos…
Tot…
ope… 607,… 495… 1,7… 1,45…
exp…
INC…
(LO… 30,2… 27,… 45,… 34,1…
FROM
OPE…
OTH…
INC…
AND
EXP…
Int… 20,6… 17,… 56,… 51,7…
exp…
Equ…
in
ear… (4,2… ) (3,… ) (12… ) (10,… )
of
joi…
ven…
Non…
cha…
in
fair
val… – 2,3… – 6,433
of
int…
rate
hed…
Debt
res…
and – – 3,3… –
ext…
exp…
Loss
(ga…
on
con…
of (7,5… ) – (7,… ) –
ima…
cen…
into
joi…
ven…
Oth…
(in… (6,2… ) (9,… ) (15… ) (24,… )
exp…
Tot…
oth… 2,749 7,1… 24,… 23,1…
(in…
exp…
INC…
(LO…
BEF… 27,5… 20,… 21,… 10,9…
INC…
TAX…
Pro…
for (8,3… ) (6,… ) (6,… ) (3,8… )
inc…
tax…
NET
INC… 19,1… 13,… 14,… 7,186
(LO…
Net
inc…
(lo…
att… 14,9… 8,4… 36,… 25,2…
to
non…
int…
NET
INC…
(LO…
ATT…
TO $ 4,153 $ 5,4… $ (21… ) $ (18,… )
RAD…
INC.
COM…
STO…
BAS…
NET
INC…
(LO…
PER
SHA… $ 0.05 $ 0.07 $ (0.… ) $ (0.24 )
ATT…
TO
RAD…
INC.
COM…
STO…
DIL…
NET
INC…
(LO…
PER
SHA… $ 0.05 $ 0.07 $ (0.… ) $ (0.24 )
ATT…
TO
RAD…
INC.
COM…
STO…
WEI…
AVE…
SHA…
OUT…
Bas… 77,9… 75,… 77,… 74,7…
Dil… 79,1… 77,… 77,… 74,7…
9
RADNET, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASHFLOWS
(IN THOUSANDS)
(unaudited)
CASH FLOWS FROM Nine Months Ended
OPERATING September 30,
ACTIVITIES 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 14,673 $ 7,186
Adjustments to
reconcile net
income to
net cash provided
by operating
activities:
Depreciation and 137,506 111,275
amortization
Noncash operating 49,425 44,605
lease expense
Equity in earnings
of joint ventures, (4,244 ) (4,590 )
net of dividends
Amortization of
deferred financing 2,355 2,242
costs
and loan discount
Loss on sale and
disposal of 9,067 3,168
equipment
Loss on
extinguishment of 407 –
debt
Gain on
contribution of (7,528 ) –
imaging centers
into joint venture
Lease abandonment 3,358 8,330
charges
Amortization of – 2,273
cash flow hedge
Non-cash change in
fair value of – 6,433
interest rate swap
Stock-based 51,933 46,276
compensation
Change in fair
value of 7,864 –
contingent
consideration
Changes in
operating assets
and
liabilities, net
of assets acquired
and
liabilities
assumed in
purchase
transactions:
Accounts (30,461 ) (20,476 )
receivable
Other current (4,292 ) 2,093
assets
Other assets (7,478 ) (2,764 )
Deferred taxes 4,334 2
Operating leases (45,252 ) (48,760 )
Deferred revenue 581 3,934
Accounts payable,
accrued expenses 81,393 53,429
and
other
Net cash provided
by operating 263,641 214,656
activities
CASH FLOWS FROM
INVESTING
ACTIVITIES
Purchase of
imaging facilities
and other (315,708 ) (66,464 )
acquisitions, net
of cash acquired
Purchase of
property and (181,721 ) (162,221 )
equipment and
other
Proceeds from sale 1,270 75
of equipment
Equity
contributions in
existing and – (4,147 )
purchase of
interest in joint
ventures
Collection of 8,541 2,832
notes receivable
Net cash used in
investing (487,618 ) (229,925 )
activities
CASH FLOWS FROM
FINANCING
ACTIVITIES
Principal payments
on notes and (13,993 ) (5,229 )
leases
payable
Payments on Term (17,028 ) (15,504 )
Loan Debt
Proceeds from
issuance of new 248,937 99,001
debt, net
of issuing costs
Purchase of
noncontrolling – 2,389
interests by
third party
Payments on
contingent (2,198 ) –
consideration and
holdbacks
Distributions paid
to noncontrolling (8,362 ) (3,313 )
interests
Proceeds from
issuance of common
stock 2,517 2,258
upon exercise of
options
Net cash provided
by financing 209,873 79,602
activities
EFFECT OF EXCHANGE
RATE CHANGES ON (2,504 ) 363
CASH
NET (DECREASE)
INCREASE IN CASH (16,608 ) 64,696
AND CASH
EQUIVALENTS
CASH AND CASH
EQUIVALENTS, 767,215 740,020
beginning of
period
CASH AND CASH
EQUIVALENTS, end 750,607 804,716
of period
SUPPLEMENTAL
DISCLOSURE OF CASH
FLOW
INFORMATION
Cash paid during
the period for $ 53,635 $ 53,679
interest
Cash paid during
the period for $ 3,908 $ 3,480
income
taxes
10
RADNET, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME ATTRIBUTABLE TO RADNET, INC. COMMON
SHAREHOLDERS TO ADJUSTED EBITDA
(IN THOUSANDS)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
inc…
(lo…
att…
to $ 4,153 $ 5,417 $ (21,… ) $ (18,… )
Rad…
Inc.
com…
sto…
Inc… 8,361 6,385 6,628 3,807
tax…
Int… 20,6… 17,3… 56,4… 51,7…
exp…
Sev… 1,193 1,441 3,317 2,614
cos…
Dep…
and 47,0… 39,7… 137,… 111,…
amo…
Non…
emp… 10,0… 9,041 51,9… 46,2…
sto…
com…
Loss
(ga…
on
sale
and 5,359 1,042 9,067 3,168
dis…
of
equ…
and
oth…
Non…
cha…
in
fair
val… – 2,371 – 6,433
of
int…
rate
hed…
Oth…
exp… (6,2… ) (9,0… ) (15,… ) (24,… )
(in…
Non…
R&D
-
Dee… 5,565 5,486 15,2… 13,8…
Clo…
OS &
Gen…
AI
Lea…
aba… 2,052 2,819 3,358 8,330
cha…
Loss
(ga…
on
con…
of (7,5… ) – (7,5… ) –
ima…
cen…
into
joi…
ven…
Loss
(ga…
on
ext…
of – – 3,368 –
debt
and
rel…
exp…
Leg… 2,815 – 2,815 –
set…
Non…
cha…
to 8,257 – 7,864 –
con…
con…
Non…
rent 604 621 2,002 2,459
exp…
Acq…
tra… 2,708 2,136 12,7… 5,109
cos…
Adj…
EBI…
- $ 105,… $ 84,8… $ 267,… $ 212,…
Rad…
Inc.
NOTE
Adj…
EBI…
- 101,… 81,4… 261,… 201,…
Ima…
Cen…
Seg…
Adj…
EBI…
- 3,046 3,452 6,827 10,5…
Dig…
Hea…
Seg…
11
PAYMENTS BY PAYOR CLASS
Third Quarter
2026
Commercial Insurance 56.4%
Medicare 24.8%
Capitation 4.9%
Medicaid 2.3%
Workers Compensation/Personal Injury 2.1%
Other* 9.5%
Total 100.0%
* Includes management fee, teleradiology and
Digital Health financial reporting unit revenue.
RADNET PAYMENTS BY MODALITY
Third Quarter Full Year Full Year Full Year
2026 2025 2024 2023
MRI 38.6% 37.7% 37.1% 36.8%
CT 15.4% 15.6% 15.9% 16.8%
PET/CT 10.2% 8.8% 7.2% 6.4%
X-ray 4.9% 5.5% 6.0% 6.5%
Ultrasound 13.4% 13.5% 13.6% 12.9%
Mammography 14.1% 15.6% 16.4% 16.0%
Nuclear Medicine 0.8% 0.9% 1.0% 0.8%
Other 2.6% 2.5% 2.7% 3.9%
100.0% 100.0% 100.0% 100.0%
PROCEDURES BY MODALITY*
Third Quarter Third Quarter
2026 2025
MRI 606,795 512,861
354,953 290,975
PET/CT 29,750 22,817
Nuclear Medicine 10,347 8,965
Ultrasound 771,224 705,347
Mammography 527,552 496,465
X-ray and Other 943,648 889,888
Total 3,244,269 2,927,318
* Volumes include wholly owned and joint venture centers.
12
RADNET, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE (3)
(IN THOUSANDS EXCEPT SHARE DATA)
(unaudited)
Three Months
Ended
2026 September 30, 2025(iv) September 30,
──────────────────────────────────────────────────────────────────────────────
NET INCOME
(LOSS)
ATTRIBUTABLE
TO $ 4,153 $ 5,417
RADNET,
INC.COMMON
STOCKHOLDERS
Non-cash
impact of – 2,587
cash flow
hedges (i)
Severance 1,194 1,441
costs
Loss (gain)
on
contribution
of imaging (7,528 ) –
centers into
joint
ventures
Non-operatio…
rent expenses 604 621
(iii)
Loss (gain)
on sale and
disposal of 5,359 1,042
equipment and
other
Intangibles
Amortization
Expense -
Digital 7,260 3,353
Health
Operating
Segment
Non-capitali…
R&D -
DeepHealth 5,565 5,486
cloud
OS &
generative AI
Legal 2,815 –
Settlement
Acquisition
transaction 2,708 2,136
costs
Non-cash
change to 8,257 –
contingent
consideration
Lease
abandonment 2,052 2,819
charges
Total
adjustments - 28,286 19.485
loss (gain)
Subtract tax
impact of (8,596 ) (6,138
Adjustments
(ii)
Tax effected
impact of 19,690 13,347
adjustments
TOTAL
ADJUSTMENT TO
NET INCOME
ATTRIBUTABLE 19,690 13,347
TO RADNET,
INC. COMMON
SHAREHOLDERS
ADJUSTED NET
INCOME (LOSS)
ATTRIBUTABLE 23,843 18,764
TO RADNET,
INC. COMMON
STOCKHOLDERS
WEIGHTED
AVERAGE
SHARES
OUTSTANDING
Diluted 79,174,226 77,388,477
ADJUSTED
DILUTED NET
INCOME PER
SHARE $ 0.30 $ 0.24
ATTRIBUTABLE
TO RADNET,
INC. COMMON
STOCKHOLDERS
Impact is the sum of (a) the loss in fair value of the hedges
during the quarter of $2,371 in 2025 and (b) the amortization of the
(i) accumulation of the changes in fair value out of Other Comprehensive
Income that existed prior to the hedges becoming ineffective of $216
in 2025.
(ii) Tax effected using 31.5% blended federal and state effective tax
rate for 2025 and 30.4% for 2026.
Represents rent expense associated with de novo sites under
(iii) construction
prior to them becoming operational.
Adjusted from what was reported during last year's third quarter
for additional addbacks of (a) $1,042,000 related to Loss (gain) on
(iv) sale and disposal of equipment and other and (b) Intangible
amortization
expense of the Digital Health operating segment of $3,353,000.
13
The Company defines Adjusted EBITDA
as earnings before interest, taxes, depreciation and amortization, each from
continuing operations and adjusted for losses or gains on
the sale of equipment, other income or loss, debt extinguishments and non-cash
equity compensation. Adjusted EBITDA includes equity earnings
in unconsolidated operations and subtracts allocations of earnings to non-
controlling interests in subsidiaries, and is adjusted for non-cash
or extraordinary and one-time events taken place during the period.
Adjusted EBITDA is reconciled to its nearest comparable
GAAP financial measure. Adjusted EBITDA is a non-GAAP financial measure used as
analytical indicator by RadNet management and the healthcare
industry to assess business performance, and is a measure of leverage capacity
and ability to service debt. Adjusted EBITDA should not
be considered a measure of financial performance under GAAP, and the items
excluded from Adjusted EBITDA should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing
or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial
performance or liquidity. As Adjusted EBITDA is not a
measurement determined in accordance with GAAP and is therefore susceptible to
varying methods of calculation, this metric, as presented,
may not be comparable to other similarly titled measures of other companies.
As noted above, the Company defines
Free Cash Flow as Adjusted EBITDA less total Capital Expenditures (whether
completed with cash or financed) and Cash Interest Expense.
Free Cash Flow is a non-GAAP financial measure. The Company uses Free Cash Flow
because the Company believes it provides useful information
for investors and management because it measures our capacity to generate cash
from our operating activities. Free Cash Flow does not
represent total cash flow since it does not include the cash flows generated by
or used in financing activities. In addition, our definition
of Free Cash Flow may differ from definitions used by other companies.
Free Cash Flow should not be considered a measure
of financial performance under GAAP, and the items excluded from Adjusted EBITDA
should not be considered in isolation or as alternatives
to net income, cash flows generated by operating, investing or financing
activities or other financial statement data presented in the
consolidated financial statements as an indicator of financial performance or
liquidity. As Adjusted EBITDA is not a measurement determined
in accordance with GAAP and is therefore susceptible to varying methods of
calculation, this metric, as presented, may not be comparable
to other similarly titled measures of other companies.
The Company defines Adjusted Earnings
(Loss) Per Share as net income or loss attributable to RadNet, Inc. common
stockholders and excludes losses or gains on the disposal of
equipment, loss on debt extinguishments, bargain purchase gains, severance
costs, loss on impairment, loss or gain on swap valuation,
gain on extinguishment of debt, unusual or non-recurring entries that impact the
Company’s tax provision and any other non-recurring
or unusual transactions recorded during the period.
Adjusted Earnings (Loss) Per Share is reconciled
to its nearest comparable GAAP financial measure. Adjusted Earnings (Loss) Per
Share is a non-GAAP financial measure used as analytical
indicator by RadNet management and the healthcare industry to assess business
performance. Adjusted Earnings Per Share should not be considered
a measure of financial performance under GAAP, and the items excluded from
Adjusted Earnings Per Share should not be considered in isolation
or as alternatives to net income, cash flows generated by operating, investing
or financing activities or other financial statement data
presented in the consolidated financial statements as an indicator of financial
performance or liquidity. As Adjusted Earnings Per Share
is not a measurement determined in accordance with GAAP and is therefore
susceptible to varying methods of calculation, this metric, as
presented, may not be comparable to other similarly titled measures of other
companies.
14